hydromethylthionine mesylate

Hydromethylthionine mesylate is a second-generation, orally administered small molecule tau aggregation inhibitor developed primarily for the treatment of Alzheimer's disease and frontotemporal dementia. It acts by selectively inhibiting the aggregation of tau protein in brain nerve cells, thereby reducing levels of aggregated or misfolded tau proteins associated with neurodegeneration. This mechanism targets the underlying pathology of diseases characterized by tau tangles, such as Alzheimer's disease. Hydromethylthionine mesylate also has a secondary mode of action that increases acetylcholine levels in the hippocampus, providing symptomatic benefit for memory functions. The drug has completed Phase 3 clinical trials (notably the LUCIDITY trial) and is under regulatory review for marketing authorization in some regions[1][3][4][5][6].

Brand names

HMTMLMTX

Other names

leuco-methylthioninium dimesylateleucomethylene blue bismesylateleucomethylene blue dimesylatehydromethylthionine mesylate